Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to $25.8 million.

  • Legend Biotech's Change in Receivables rose 10867.38% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72000.0, marking a year-over-year decrease of 12517.48%. This contributed to the annual value of $93.8 million for FY2024, which is 19472.01% up from last year.
  • Latest data reveals that Legend Biotech reported Change in Receivables of $25.8 million as of Q3 2025, which was up 10867.38% from -$26.2 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Change in Receivables registered a high of $96.7 million during Q1 2024, and its lowest value of -$99.0 million during Q4 2023.
  • For the 5-year period, Legend Biotech's Change in Receivables averaged around $4.0 million, with its median value being $34000.0 (2023).
  • Per our database at Business Quant, Legend Biotech's Change in Receivables plummeted by 31941612.9% in 2023 and then surged by 28441176.47% in 2024.
  • Over the past 5 years, Legend Biotech's Change in Receivables (Quarter) stood at -$48.9 million in 2021, then soared by 99.94% to -$31000.0 in 2022, then plummeted by 319416.13% to -$99.0 million in 2023, then soared by 94.36% to -$5.6 million in 2024, then skyrocketed by 562.02% to $25.8 million in 2025.
  • Its Change in Receivables was $25.8 million in Q3 2025, compared to -$26.2 million in Q2 2025 and $5.9 million in Q1 2025.